


Pirfenidone-D5

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 1020719-62-3 |
| Formula: | C ₁₂ H ₆ D ₅ NO |
| Molecular Weight: | 190.25 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|---------------|---|
| Description | Pirfenidone-D5 is a deuterium labeled Pirfenidone. Pirfenidone (T2386) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. |
| Targets(IC50) | CCR,TGF-beta/Smad |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 5.2562 mL | 26.2812 mL | 52.5624 mL |
| 5 mM | 1.0512 mL | 5.2562 mL | 10.5125 mL |
| 10 mM | 0.5256 mL | 2.6281 mL | 5.2562 mL |
| 50 mM | 0.1051 mL | 0.5256 mL | 1.0512 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Burghardt I, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. *Biochem Biophys Res Commun.* 2007 Mar 9;354(2):542-7.
- Nakazato H, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. *Eur J Pharmacol.* 2002 Jun 20;446(1-3):177-85.
- Inomata M, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. *Respir Res.* 2014 Feb 8;15:16.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481